|Preferred IUPAC name
3D model (JSmol)
|Molar mass||453.538 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
IMP-1088 is an enzyme inhibitor of the human N-myristoyltransferases NMT1 and NMT2 capable of preventing rhinoviral replication, an area of research relating to potential treatment of the common cold. IMP-1088 works to keep cells from generating infectious virus by targeting the cell instead of the rhinovirus itself. It does this by blocking the NMT protein of the host cell which prevents the virus from assembling its capsid, since viral capsid myristoylation by host NMT is essential for assembly. It is thought unlikely that viruses will evolve resistance to such an approach since IMP-1088 works against the human cell and not the virus.
- ^ Mousnier, Aurélie; Bell, Andrew S.; Swieboda, Dawid P.; Morales-Sanfrutos, Julia; Pérez-Dorado, Inmaculada; Brannigan, James A.; Newman, Joseph; Ritzefeld, Markus; Hutton, Jennie A.; Guedán, Anabel; Asfor, Amin S.; Robinson, Sean W.; Hopkins-Navratilova, Iva; Wilkinson, Anthony J.; Johnston, Sebastian L.; Leatherbarrow, Robin J.; Tuthill, Tobias J.; Solari, Roberto; Tate, Edward W. (14 May 2018). "Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus". Nature Chemistry. 10 (6): 599–606. Bibcode:2018NatCh..10..599M. doi:10.1038/s41557-018-0039-2. PMC 6015761. PMID 29760414.
- ^ Borman, Stu. "Agent stops common cold virus replication". Chemical & Engineering News. Retrieved 20 May 2018.
- ^ Houser, Kristin (19 May 2018). "A team of researchers may have actually found a cure to the common cold". Business Insider. Retrieved 20 May 2018.